M
Mads Ravnborg
Researcher at Odense University Hospital
Publications - 44
Citations - 3577
Mads Ravnborg is an academic researcher from Odense University Hospital. The author has contributed to research in topics: Multiple sclerosis & Expanded Disability Status Scale. The author has an hindex of 23, co-authored 44 publications receiving 3380 citations. Previous affiliations of Mads Ravnborg include Copenhagen University Hospital & University of Southern Denmark.
Papers
More filters
Journal ArticleDOI
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial
Giancarlo Comi,Vittorio Martinelli,M. Rodegher,Lucia Moiola,Ovidiu Bajenaru,A. Carra,Irina Elovaara,Franz Fazekas,H.-P. Hartung,Jan Hillert,John King,Sámuel Komoly,Catherine Lubetzki,Xavier Montalban,Kjell-Morten Myhr,Mads Ravnborg,Peter Rieckmann,Daniel Wynn,Carolyn A Young,Massimo Filippi +19 more
TL;DR: Early treatment with glatiramer acetate is efficacious in delaying conversion to clinically definite multiple sclerosis in patients presenting with clinically isolated syndrome and brain lesions detected by MRI.
Journal ArticleDOI
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
Ludwig Kappos,David W. Bates,Gilles Edan,Mefkure Eraksoy,Antonio Garcia-Merino,Nikolaos Grigoriadis,Hans Peter Hartung,Eva Havrdova,Jan Hillert,Reinhard Hohlfeld,Marcelo Kremenchutzky,Olivier Lyon-Caen,Ariel Miller,Carlo Pozzilli,Mads Ravnborg,Takahiko Saida,Christian Sindic,Karl Vass,David B. Clifford,Stephen L. Hauser,Eugene O. Major,Paul O'Connor,Howard L. Weiner,Michel Clanet,Ralf Gold,Hans H. Hirsch,Ernst W. Radü,Per Soelberg Sørensen,John King +28 more
TL;DR: This Review revisits and update previous recommendations on natalizumab for treatment of patients with RRMS, based on additional long-term follow-up of clinical studies and post-marketing observations, including appropriate patient selection and management recommendations.
Journal ArticleDOI
Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.
Per Soelberg Sørensen,Christian Ross,Katja Maria Clemmesen,Klaus Bendtzen,Jette L. Frederiksen,Kai Jensen,Ole Kristensen,Thor Petersen,Soren Rasmussen,Mads Ravnborg,Egon Stenager,Nils Koch-Henriksen +11 more
TL;DR: In this paper, the authors measured neutralising antibodies every 12 months for up to 60 months in 541 patients with multiple sclerosis, randomly selected from all patients who started treatment with interferon beta between 1996 and 1999.
Journal Article
[Clinical importance of neutralising antibodies against interferon-beta in patients with relapsing-remitting multiple sclerosis].
Soelberg Sørensen,N. Koch-Henriksen,Christian Ross Pedersen,Katja Maria Clemmesen,Klaus Bendtzen,Jette L. Frederiksen,Kai Jensen,Ole Kristensen,Thor Petersen,Søren K. Rasmussen,Mads Ravnborg,Egon Stenager,Dansk Multipel Sklerose Gruppe +12 more
TL;DR: The findings suggest that the presence of neutralising antibodies against interferon beta reduces the clinical effect of the drug, which should prompt consideration about change of treatment in patients who are not doing well on interferons beta.
Journal ArticleDOI
Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis.
Per Soelberg Sørensen,Benedikte Wanscher,C. V. Jensen,Karen Schreiber,Morten Blinkenberg,Mads Ravnborg,H. Kirsmeier,V. A. Larsen,M. L. Lee +8 more
TL;DR: The results suggest that IVIG treatment is beneficial to patients with relapsing MS, and the number of adverse events, in particular eczema, was significantly higher during IVIG therapy than during placebo treatment.